(Q44592465)

English

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy

scientific article published on 3 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy (English)

1 reference

Europe PubMed Central

4 December 2017

Alton B. Farris

9

1 reference

Europe PubMed Central

4 December 2017

author name string

Sarah B Fisher

1

1 reference

Europe PubMed Central

4 December 2017

Kevin E Fisher

2

1 reference

Europe PubMed Central

4 December 2017

Sameer H Patel

3

1 reference

Europe PubMed Central

4 December 2017

Matthew G Lim

4

1 reference

Europe PubMed Central

4 December 2017

David A Kooby

5

1 reference

Europe PubMed Central

4 December 2017

Bassel F El-Rayes

6

1 reference

Europe PubMed Central

4 December 2017

Charles A Staley

7

1 reference

Europe PubMed Central

4 December 2017

N Volkan Adsay

8

1 reference

Europe PubMed Central

4 December 2017

Shishir K Maithel

10

1 reference

Europe PubMed Central

4 December 2017

language of work or name

0 references

publication date

3 July 2012

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

119

1 reference

Europe PubMed Central

4 December 2017

454-462

1 reference

Europe PubMed Central

4 December 2017

2

1 reference

Europe PubMed Central

4 December 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Management of gallbladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Biliary tract cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Biliary tract cancers: current concepts and controversies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Current management of gallbladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiot

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Cellular pharmacology of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Molecular predictors of response to chemotherapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

21 January 2018

Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

7 January 2021

based on heuristic

inferred from DOI database lookup

Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27739

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27739

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44592465&oldid=2028828100"